Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 2676 of 3330
Next
>>
>
66876 to 66900 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
MCF 10F	NM	-	Sirolimus	MTOR	MTOR	1.33	uM	7488.068	0.6806	0.5058	1.3560
MCF 10F	NM	-	Sirolimus	MTOR	MTOR	6.67	uM	7488.068	0.7294	0.5848	1.3560
MCF 10F	NM	-	Sirolimus	MTOR	MTOR	33.3	uM	7488.068	0.6973	0.5330	1.3560
MCF 10F	NM	-	Sirolimus	MTOR	MTOR	167	uM	7488.068	0.6465	0.4498	1.3560
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	0.000427	uM	7489.068	0.9834	0.9837	2.0392
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	0.00213	uM	7489.068	0.8299	0.8252	2.0392
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	0.0107	uM	7489.068	0.8013	0.7941	2.0392
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	0.0533	uM	7489.068	0.7101	0.6909	2.0392
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	0.267	uM	7489.068	0.7457	0.7320	2.0392
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	1.33	uM	7489.068	0.6947	0.6729	2.0392
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	6.67	uM	7489.068	0.7136	0.6950	2.0392
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	33.3	uM	7489.068	0.6239	0.5869	2.0392
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	167	uM	7489.068	0.5286	0.4631	2.0392
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	0.000427	uM	7491.068	0.9173	0.6978	0.5270
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	0.00213	uM	7491.068	0.8637	0.5145	0.5270
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	0.0107	uM	7491.068	0.7514	0.1629	0.5270
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	0.0533	uM	7491.068	0.6830	-0.0300	0.5270
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	0.267	uM	7491.068	0.7221	0.0783	0.5270
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	1.33	uM	7491.068	0.6754	-0.0502	0.5270
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	6.67	uM	7491.068	0.7217	0.0770	0.5270
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	33.3	uM	7491.068	0.6619	-0.0858	0.5270
MCF12A	NM	Basal B	Sirolimus	MTOR	MTOR	167	uM	7491.068	0.5983	-0.2455	0.5270
MCF7	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0000853	uM	7492.069	0.9565	0.9495	1.7373
MCF7	HR+	Luminal	Sirolimus	MTOR	MTOR	0.000427	uM	7492.069	0.9676	0.9624	1.7373
MCF7	HR+	Luminal	Sirolimus	MTOR	MTOR	0.00213	uM	7492.069	0.8647	0.8395	1.7373

|<
<<
Previous
Page 2676 of 3330
Next
>>
>
66876 to 66900 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)